Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.
Stocks · News reference
8-K filing — Hinge Health, Inc. (HNGE)
Filed: 2026-08-21 AccNo: 0001628280-26-058439 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Needham Maintains Buy on Hinge Health, Raises Price Target to $115
Needham analyst Ryan MacDonald maintains Hinge Health (NYSE:HNGE) with a Buy and raises the price target from $97 to $115.
Baird Maintains Neutral on Hinge Health, Raises Price Target to $90
Baird analyst Vikram Kesavabhotla maintains Hinge Health (NYSE:HNGE) with a Neutral and raises the price target from $85 to $90.
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
Hinge Health (HNGE) raised its 2026 revenue guidance to $856-$860M following a 53% Q2 revenue jump to $212.8M. The company is expanding beyond its core MSK platform into Migraine Care (450 clients, 5M lives) and acquiring Cylinder Health for $105M to accelerate GI expansion. While growth prospects remain strong with a 30.6% expected growth rate, continued product investments and integration costs could temper margin expansion.